| |
Apply advanced AI/ML methodologies to improve equity through data-informed site selection. Learn how to meet your enrollment diversity goals in this new insight brief — Download now. 
|
|
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
| By Zoey Becker Over his first term, Donald Trump advocated for lower drug prices and pharmacy benefit manager reform. Now with the Inflation Reduction Act in play, what's to come for pharma under a Trump administration? |
|
|
|
By Gabrielle Masson Kymera Therapeutics is pivoting its focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 through partnerships. |
By Fraiser Kansteiner Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair. |
By James Waldron Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. |
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join West experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now. 
|
|
By Angus Liu An FDA investigation last year into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. Now, less than a year later, the FDA is reconsidering those serious safety warnings with plans to potentially change them, CBER Director Peter Marks, M.D., Ph.D., said in an interview with Fierce Pharma. |
By Conor Hale LumiThera’s Valeda system relies on photobiomodulation, or the use of different wavelengths of light to stimulate activity in the cells of the retina. |
By James Waldron Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist. |
By Joseph Keenan The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. |
By Ben Adams With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. |
By Darren Incorvaia Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the company announced Nov. 4. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy. |
|
|---|
|
|
|
Tuesday, November 19, 2024 | 2pm ET / 11am PT Join us to learn about the latest strategies and solutions for storing, accessing and using data more effectively. Discover how the scientific community can now open the door to an array of choices for rapidly performing complex analyses on massive data sets, building and training generative AI models, and protecting and securing critical data stores. Register now. 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Direct-To-Patient Cash Solutions for Pharma Manufacturers – learn how to leverage cash models strategically to mitigate access challenges and overcome the hurdles faced in today’s retail pharmacy environment. Sponsored by: KnippeRx |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
Survey Explore the latest trends in compliance monitoring to help your team embrace proactive strategies in key areas of risk management. Stay ahead of the ever-evolving landscape and new policies to enhance your compliance program. Sponsored by: IQVIA |
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
